HOME >> MEDICINE >> NEWS
Grueling four-day race becomes Stanford lab for cardiac experiments

Stanford, Calif. -- Stanford cardiologist Euan Ashley wanted to study the hearts of endurance athletes, so he set up a mobile heart lab at the finishing line of the ultra-endurance race "Adrenalin Rush" in the Scottish Highlands and waited for the racers to come in.

At about 2 a.m. on Aug. 1, 2001, the winning team of four athletes collapsed across the finishing line after 90 continuous hours of biking, climbing, swimming, paddling and rope work with virtually no sleep. "We waited in the cold and wet and literally picked them up at the end of the race," said Ashley, who then fed the athletes donuts, tested their hearts and waited for the remaining athletes to arrive.

After testing the hearts of about 50 endurance athletes both before and after the 400-km race in Stirling, Scotland, Ashley, MD, PhD, assistant professor of cardiology at the Stanford University School of Medicine, and his colleagues found that contrary to generally held beliefs, the heart does, in fact, tire with exercise - at least it can under extreme conditions.

"I think it's amazing," said Ashley. "Your heart beats 3 billion times in a lifetime. In the absence of disease, we don't think of an 80- or 90-year-old's heart tiring."

The results of the study, to be published in the Aug.1 issue of the Journal of the American College of Cardiology, not only show that hearts can tire with exercise, but also that one particular gene variant can predict the extent to which the heart will tire.

"It was a bit of a labor of love to find this out," said Ashley, a native of Scotland who recruited scientists from Oxford and Duke, not to mention members of his own family, to help with the study. His wife and his father also waited at the finish line to take blood samples as the racers stumbled in.

"Our place became the hangout," Ashley said. "We had guys sleeping on the floor. We sent out two or three times for more donuts as finishers came in."

<
'"/>

Contact: Tracie White
traciew@stanford.edu
650-723-7628
Stanford University Medical Center
25-Jul-2006


Page: 1 2 3

Related medicine news :

1. Health effects of functional foods featured during four-day symposium, Sept. 10-13
2. Oslo press event launches 46664 Arctic and spearheads a four-day spotlight on Africa
3. MRI finds breast cancer before it becomes dangerous
4. National ICD Registry becomes official database for Medicare
5. HUP becomes first in region to implant a HeartMate II Left Ventricular Assist System into a patient
6. Stanford researchers find culprit in aging muscles that heal poorly
7. Old McDonalds has a hold on kids taste buds, Stanford/Packard study finds
8. Aging stem cells in mice may hold answers to diseases of the aged, Stanford study finds
9. Stanford researchers track human stem cells transplanted into rat brain
10. Once-fatal metabolic disorders treatable, says Stanford/Packard researcher
11. Tiny newborns face higher risk of death at community hospitals, Stanford/VA study finds

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Grueling four day race becomes Stanford lab for cardiac experiments

(Date:7/30/2014)... New York City, NY (PRWEB) July 30, 2014 ... Memorial & Museum at Ground Zero, the Ground Zero Museum ... confusion in recent tour bookings. Says the Museum Workshop's Carole ... tour and museum on all the major travel sites who ... Our description is now crystal clear as to what we ...
(Date:7/30/2014)... NY, July 30, 2014We have pills to ease pain, to ... conditions, and to enhance our sexual and athletic prowess. Why ... and could we benefit from taking fewer pills? This provocative ... The Role and Fantasy of Pills in Modern Medicine ," ... , a peer-reviewed publication from Mary Ann Liebert, Inc., publishers. ...
(Date:7/30/2014)... WEDNESDAY, July 30, 2014 (HealthDay News) -- Medical costs ... States are more than $32 billion each year, according ... Control and Prevention. The yearly financial toll of ... to reach an estimated $49 billion by 2020. ... for COPD, which provide state public health practitioners with ...
(Date:7/30/2014)... in Manchester have identified a protein that could help ... a treatment that makes radiotherapy more effective, according to ... Cancer (BJC). , The team from The University ... that patients whose bladder tumour had high levels of ... from having carbogen oxygen mixed with carbon dioxide ...
(Date:7/30/2014)... Up to 20 percent of Parkinson,s disease (PD) ... but largely unrecognized challenge: the occurrence of impulse ... behavior, eating, or spending. Yet the presence of ... complicate treatment options. A team of investigators from ... of Pennsylvania and the Parkinson,s Disease Research, Education ...
Breaking Medicine News(10 mins):Health News:Despite Some Confusion over 9/11 Memorial Opening, Kid-Friendly Ground Zero Museum Workshop on 14th Street Continues It's Mission 2Health News:Despite Some Confusion over 9/11 Memorial Opening, Kid-Friendly Ground Zero Museum Workshop on 14th Street Continues It's Mission 3Health News:Despite Some Confusion over 9/11 Memorial Opening, Kid-Friendly Ground Zero Museum Workshop on 14th Street Continues It's Mission 4Health News:Despite Some Confusion over 9/11 Memorial Opening, Kid-Friendly Ground Zero Museum Workshop on 14th Street Continues It's Mission 5Health News:Annual COPD Costs To Hit $49 Billion by 2020: CDC 2Health News:Scientists pinpoint bladder cancer patients who could benefit from 'tumor-softening' treatment 2Health News:Penn researchers: Naltrexone may diminish impulse control disorders in Parkinson's disease patients 2
(Date:7/30/2014)... 30, 2014 Stryker brand ambassadors Fred Funk ... 3M Championship Champions Tour event near Minneapolis, MN ... Blaine . Stryker is the official joint replacement products company ... Friday, August 1 st through Sunday, August 3 rd , ... on-site joint health destination located in the Pioneer Press Expo tent ...
(Date:7/30/2014)... PARIS , July 30, 2014 /PRNewswire/ ... Sanofi (EURONEXT: SAN and NYSE: SNY ) ... of alirocumab in people with hypercholesterolemia met their primary ... in low-density lipoprotein cholesterol (LDL-C) at 24 weeks compared ... monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9). ...
(Date:7/30/2014)... and SAN DIEGO , July 30, 2014 ... ARNA ) announced today that an article based on post-hoc ... entitled, "Early Weight Loss While on Lorcaserin, Diet, and Exercise ... published in the online issue of Obesity , the ... of these analyses was to identify whether there is an ...
Breaking Medicine Technology:Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 2Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 3Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 4Stryker Brand Ambassadors Fred Funk And Hal Sutton Set To Play At 3M Championship 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 2Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 3Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 4Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 5Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 6Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 7
Cached News: